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Abstract
Background: Photodynamic therapy (PDT) is a promising cancer treatment modality that involves
the interaction of the photosensitizer, molecular oxygen and light of specific wavelength to destroy
tumor cells. Treatment induced hypoxia is one of the main side effects of PDT and efforts are
underway to optimize PDT protocols for improved efficacy. The aim of this study was to investigate
the anti-tumor effects of PDT plus Erbitux, an angiogenesis inhibitor that targets epidermal growth
factor receptor (EGFR), on human bladder cancer model. Tumor-bearing nude mice were assigned
to four groups that included control, PDT, Erbitux and PDT plus Erbitux and tumor volume was
charted over 90-day period.
Results: Our results demonstrate that combination of Erbitux with PDT strongly inhibits tumor
growth in the bladder tumor xenograft model when compared to the other groups.
Downregulation of EGFR was detected using immunohistochemistry, immunofluorescence and
western blotting. Increased apoptosis was associated with tumor inhibition in the combination
therapy group. In addition, we identified the dephosphorylation of ErbB4 at tyrosine 1284 site to
play a major role in tumor inhibition. Also, at the RNA level downregulation of EGFR target genes
cyclin D1 and c-myc was observed in tumors treated with PDT plus Erbitux.
Conclusion: The combination therapy of PDT and Erbitux effectively inhibits tumor growth and
is a promising therapeutic approach in the treatment of bladder tumors.
Background
Photodynamic therapy (PDT) is a treatment modality that
involves the administration of a tumor-localizing photo-
sensitizer followed by light irradiation of specific wave-
length that matches the absorption characteristics of the
photosensitizer, thereby producing cytotoxic intermedi-
ates that damage cellular structures [1]. The advantages of
PDT include selective targeting, minimal invasiveness and
reduced toxicity that allows for repeated treatment [2,3].
However during PDT, tumor oxygen is depleted due to
vascular damage and oxygen consumption, which causes
hypoxia within the surviving tumor cells thus triggering
angiogenesis [4,5]. Angiogenesis is the sprouting of new
smaller vessels from the pre-existing vasculature. Not only
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is angiogenesis essential for tumor growth but it also ena-
bles the migration of tumor cells to distant sites, forming
metastases [6].
Bladder cancer is the 9th most common cancer affecting
Singapore men [7]. Current treatment options include
surgery, chemotherapy or immunotherapy, and radiation
therapy [8]. Efforts are on going to develop therapeutic
tools that allow the preservation of bladder and to control
the rate of recurrences. Clinical trials with PDT have
shown promising results in the treatment of bladder can-
cer, especially for flat malignant lesions such as carcinoma
in situ [9,10]. Recently, significant progress has also been
made to understand the molecular and genetic events
underlying bladder cancer [11]. Epidermal growth factor
receptor (EGFR) is one such molecular marker that has
been widely reported in bladder carcinoma [12,13].
Upregulated EGFR signaling is known to initiate a cascade
of events leading to cell proliferation, migration, invasion
[14] and blocking of apoptosis [15] that eventually leads
to tumor progression. Many epithelial cancers have been
found to overexpress EGFR, including head and neck,
breast, colon, lung, prostate, kidney and bladder [16].
Studies show that antibodies that block the EGF binding
site of EGFR inhibit tumor cell proliferation [17]. There-
fore, blocking EGFR along with conventional cancer ther-
apies could be an attractive anti-tumor strategy.
Erbitux (cetuximab), a chimeric human-murine mono-
clonal antibody, competitively binds to the accessible
extracellular domain of EGFR and inhibits dimerisation
and subsequently inhibits cell proliferation, tumor
growth and metastasis [18]. In most studies, the use of
Erbitux, as an anti-EGFR therapy in combination with
chemotherapy and radiotherapy has demonstrated signif-
icant clinical efficacy, due to its good tolerability and non-
overlapping toxicities [19]. Also, in vivo therapies with
Erbitux and chemotherapy drugs resulted in a greater
regression of bladder tumor growth compared with either
agent alone [20]. In the present study we have evaluated
the anti-tumor effect of Erbitux in combination with PDT
on bladder carcinoma xenograft model. Our findings
indicate that combining PDT and Erbitux significantly
enhances the anti-tumor activity, by inhibiting EGFR
expression, increasing apoptosis and by dephosphorylat-
ing essential EGFR tyrosine sites. These results may pro-
vide a rationale for evaluating the combination of PDT
and Erbitux as a cancer treatment modality in a clinical
setting.
Results
Tumor regression
To investigate the long-term effectiveness of PDT and
Erbitux, we employed MGH bladder tumor xenograft
model in athymic nude mice. Tumors were allowed to
grow to sizes of 6-7 mm in diameter before PDT treatment
was carried out and were measured three times a week and
charted for 90 days (Figure 1). The total tumor volume for
each group equals the sum of individual tumor volumes,
which in our case were 8-10 individual tumors. Tumor
inhibition was calculated on day 29 when the control
tumors reached maximum volume of 2 cm3. The mean
relative tumor inhibition of 93% (95% CI - 87.7 to 98) (p
< 0.001) was observed in tumors treated with the combi-
nation therapy of PDT plus Erbitux when compared with
control tumors. A week after treatment, accelerated tumor
growth was noticed in the combination therapy group,
but there was a decrease thereafter in tumor size, resulting
in complete tumor regression. The tumors treated with
PDT only and Erbitux only, exhibited 57.8% (95% CI -
49.2 to 66.4) and 74.8% (95% CI - 68.7 to 80.8) mean
tumor inhibition respectively. Compared to control, the
overall tumor response was greater in the monotherapy
groups of PDT only and Erbitux only, though the differ-
ence between the monotherapy groups were not signifi-
cant. The treatment modalities in our study did not induce
any signs of toxicity such as excessive weight loss, diarrhea
or vomiting in the animals. No treatment-related death
occurred.
Detection of EGFR in tumor tissue
To investigate the anti-tumor activity of the treatments,
EGFR expression was evaluated using western blotting.
The results obtained were confirmed by immunohisto-
chemistry (IHC) and immunofluorescence (IF) tech-
niques. Tumors were harvested from the animals between
Mean tumor volume charted against number of days post  treatment, to assess the tumor response in various treat- ment groups Figure 1
Mean tumor volume charted against number of days 
post treatment, to assess the tumor response in vari-
ous treatment groups. The combination therapy group of 
PDT and Erbitux exhibited greatest tumor response in com-
parison with all other groups. Each group represents the 
mean response (bars, SE) of 10 animals.Molecular Cancer 2009, 8:94 http://www.molecular-cancer.com/content/8/1/94
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25-90 days, based on the maximum tumor volume limit
or the completion of treatment. EGFR expression ana-
lyzed using immunoblotting was found to be lower in the
PDT plus Erbitux group (p < 0.001) compared to control,
PDT only and Erbitux only groups (Figure 2). IHC and IF
results showed similar trends in which the combination
of PDT and Erbitux resulted in significant reduction of
EGFR expression at 4-6% (EGFR score 1) compared to
monotherapy and control groups. Maximum EGFR tumor
cell membrane staining of 21-24% (EGFR score 3) was
noticed in the untreated tumors. The monotherapy
groups of PDT only and Erbitux only, exhibited 15-17%
(EGFR score 2) and 11-13% (EGFR score 2) staining
respectively (Figures 3 and 4).
Determination of apoptosis
To determine whether the observed tumor growth sup-
pression was caused by apoptotic cell death, a terminal
deoxynucleotidyl transferase mediated dUTP nick-end-
labeling (TUNEL) assay was performed (Figure 5). The
tunnel assay was performed on the tumors that were har-
vested from the animals at the end of the treatment. Few
isolated positive nuclei were noticed in untreated tumors
(Apoptotic index (AI) - 6%). Both PDT only (AI - 14%)
and Erbitux only (AI - 16%) treated tumors showed
increased apoptosis compared to control. High levels of
apoptotic nuclei were clearly exhibited by tumors treated
with the PDT plus Erbitux combination therapy (AI - 32%,
p < 0.001).
EGFR phosphorylation
To gain better understanding of the potential mechanisms
of Erbitux and PDT treatments, we investigated the phos-
phorylation status of EGFR sites (Figure 6). Phosphoryla-
tion of EGFR can occur at different tyrosine sites that can
lead to subsequent activation of different pathway.
Increased phosphorylation of ErbB2(Thr686),
ErbB2(Ser1113) and limited phosphorylation of
EGFR(Thy845), ErbB2(Tyr1221/1222), ErbB3(Tyr1289)
and ErbB4(Tyr1284) sites was seen in the control group.
In the monotherapy groups, ErbB2(Thr686), (Ser113)
and ErbB4(Tyr1284) sites were phosphorylated. Inhibi-
tion of most of the EGFR phosphorylation sites was
observed in combination therapy groups except for
ErbB2(Thr686) and (Ser1113). Though, phosphorylation
at site Thr686 was greater than Ser1113.
Expression of EGFR target genes
The effect of EGFR inhibition on target genes cyclin-D1, c-
myc was evaluated at the RNA level (figure 7). Cyclin D1
is an important regulator of G1 to S-phase transition and
overexpression of cyclin D1 has been linked to the devel-
opment and progression of cancer. c-myc is activated in a
variety of tumor cells and plays an important role in cel-
lular proliferation, differentiation, apoptosis and cell
cycle progression. Downregulation of cyclin-D1 and c-
myc was observed in the tumors treated with PDT and
Erbitux (p < 0.05) when compared with the other groups.
Discussion
PDT is being successfully used in clinics for the treatment
of superficial lesions of both malignant and non-malig-
nant diseases. However, treating solid tumors is still a
challenge due to issues related to penetration of light,
non-homogeneity and geometry of the tumors [21]. Trig-
gering of angiogenesis is also dependent on different PDT
parameters such as drug/light dosage and drug light inter-
val. Previous studies have shown that sub-optimal PDT
elicits increased angiogenesis [22,23]. In our earlier study
we have reported that high dose light PDT with high flu-
ence rate induces the overexpression of VEGF compared to
low dose light PDT [24]. We have also noticed that pre-
dominantly cellular targeting long drug light interval PDT
can induce greater expression of angiogenic proteins com-
pared to vascular targeting short drug light interval PDT
[25]. Therefore, there is a need for continued investigation
to enhance the anti-tumor efficacy of PDT for improved
response and expanded use. In this study, we evaluate the
use of EGFR inhibitor Erbitux in combination with PDT to
improve the tumor responsiveness in a bladder tumor
xenograft model.
Bladder cancer treatment remains a challenge though sig-
nificant progress has been made in the prevention of dis-
ease progression and the improvement of patient survival
rates. PDT has been successfully used to treat recurrent or
drug resistant superficial bladder cancer. 5-aminolevulinic
acid (ALA)-PDT has shown to be an effective treatment
option for patients with superficial bladder cancer [26].
However, ALA-PDT can cause pain and would require
some form of local anesthesia. Some investigators have
concluded that in most clinical trials of bladder cancer,
the PDT treatment was overly aggressive and resulted in
long lasting and severe urinary complications [27]. Nseyo
et al. [28] suggested multiple treatments at lower drug and
light doses to reduce the incidence and severity of symp-
toms following PDT of superficial bladder cancer. Single
session whole bladder PDT using diffusion medium for
isotropic light distribution was beneficial for patients
treated with TCC refractory to traditional intravesical ther-
apy [29]. However, patients with extensive flat papillary
lesions did not appear to respond well. As can be seen,
PDT treatment of bladder cancers continues to present
major challenges and novel therapeutical approaches
need to be explored.
Erbitux was approved by the US Food and Drug Adminis-
tration (FDA) for use in combination with irinotecan for
the treatment of metastatic colorectal cancer and it is also
being used for the treatment of metastatic squamous cellMolecular Cancer 2009, 8:94 http://www.molecular-cancer.com/content/8/1/94
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carcinoma of the head and neck (SCCHN) [30,31].
Results of a large phase II study on irinotecan-refractory
colorectal cancer patients have shown a significant
response of 22.9% when Erbitux was combined with
chemotherapy agent, irinotecan [32]. In another study,
the response rate was significantly improved when Erbitux
was combined with cisplatin in the first-line treatment of
recurrent or metastatic SCCHN [33]. A randomized trial
that compared radiotherapy plus Erbitux with radiother-
apy alone in patients with stage III or IV non-metastatic
SCCHN, demonstrated significantly longer locoregional
control with radiotherapy plus Erbitux than with radio-
therapy alone; moreover, progression-free survival were
significantly longer and the overall response rate was sig-
nificantly better with the combination therapy [34].
Recent results from a phase III randomised study demon-
strated that the Erbitux given concomitantly with radio-
therapy yields a significant clinical benefit over
radiotherapy alone without any increase in radiotherapy-
associated toxicity [35].
In our in vivo tumor regression study, we demonstrate
that the combination therapy of Erbitux with PDT can
improve the tumor response by attenuating the ang-
iogenic process. A similar study conducted on a mouse
model of human ovarian cancer in which C225 (Erbitux)
was combined with PDT regimen produced synergistic
reductions in mean tumor burden and significantly
increased median survival [36]. In this study, PDT treated
tumors did not exhibit significant tumor regression com-
pared to combination therapy groups and this could be
attributed to the high fluence rate that was administered
during PDT. High fluence rate can deplete tumor oxygen
to a large extent, thereby stimulating the production of
stress induced survival molecules that reduce the effective-
ness of PDT and affect tumor control [4]. More impor-
tantly, the administration of high light dose for this
experiment was to test our hypothesis that combining
PDT with Erbitux can improve tumor control and also to
evaluate the effectiveness of Erbitux in reducing EGFR
concentrations. Our investigations have indicated that
Erbitux alone as monotherapy was not effective in con-
trolling tumor growth. One of the possible reasons for this
observation could be the fact that tumors overexpressing
EGFR might not be sensitive to Erbitux. Although we
would assume that tumors overexpressing EGFR would
respond well to anti-EGFR therapy, studies have demon-
strated that the level of EGFR expression does not have
any impact on tumor response rates as a significant
number of EGFR-positive tumors could be resistant to
Erbitux [37,38]. The group that received the combination
therapy of PDT and Erbitux exhibited accelerated growth
a week after PDT which could be due to an increase in the
expression of angiogenic growth factors either due to
hypoxia, induced by oxygen depletion during PDT light
irradiation or incomplete treatment. Our earlier results
have shown increased expression of angiogenic growth
factor VEGF at 72 h post PDT [39]. In this study, the regu-
lar administration of Erbitux after PDT treatment could
have blocked the EGFR pathway and reduced angiogen-
esis. Therefore, our data supports the hypothesis that
combination therapy of PDT and Erbitux would be more
effective in preventing angiogenesis compared to mono-
therapy alone.
To further substantiate our results we performed western
blotting, immunohistochemistry and immunofluores-
cence to determine the EGFR levels in all the treatment
groups. EGFR immunoreactivity was localized mainly in
the cell membranes and to a lower extent in the cyto-
plasm. It has been well established that the core of solid
tumors is hypoxic, and that hypoxic tumor environment
is sufficient to trigger EGFR expression in tumors [40].
Previous studies have reported the downregulation of
EGFR after PDT [41,42]; in marked contrast our results
Expression of EGFR in the tumors was detected using west- ern immunoblot analysis Figure 2
Expression of EGFR in the tumors was detected 
using western immunoblot analysis. Expression of actin 
was used to monitor protein loading. Ratio of EGFR density 
plotted against actin. Combination modality of PDT plus 
Erbitux was effective in reducing the expression of EGFR in 
the tumor tissue.Molecular Cancer 2009, 8:94 http://www.molecular-cancer.com/content/8/1/94
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demonstrated an increase in EGFR expression post hyper-
icin-mediated PDT. This observation could be attributed
to numerous reasons such as the light/drug dosage, the
complexity of tumor microenvironment and the proper-
ties of the photosensitizer [4]. Combined antitumor activ-
ity of Erbitux with standard chemotherapy and
radiotherapy is well documented in the treatment of dif-
ferent types of tumors and is reported to be more effica-
cious than individual monotherapies [19]. In this study,
combination modality of PDT and Erbitux was effective in
reducing the expression of EGFR and that could have lead
to the regression of tumors in this group.
In the current study, we have also shown that PDT plus
Erbitux increased apoptosis in the treated tumors com-
pared to PDT only and inhibitor only monotherapies.
Erbitux has been known to increase apoptosis in various
tumor models by different mechanisms, including upreg-
ulation of pro-apoptotic Bax protein [43], decrease in the
expression of anti-apoptotic molecule Bcl-2 [44] and the
activation of pro-apoptotic caspases [45]. Hypericin-PDT
is also known to induce apoptosis in a dose-dependent
manner with higher doses leading to necrosis. Based on
the lack of tumor inhibition in the monotherapy groups,
it can be noted that tumors treated with PDT alone and
Erbitux alone induced limited apoptosis in bladder carci-
noma tumors. Therefore in this investigation, it was
observed that the combination therapy significantly
increased tumor cell apoptosis and inhibited tumor pro-
gression. Preclinically, many studies have shown that
treatment with Erbitux in combination with radiotherapy
or chemotherapy enhances apoptotic cell death than indi-
vidual therapies. In a similar manner, PDT induced apop-
tosis, could have been enhanced by the combination of
Erbitux to the treatment regime.
By using EGF phosphorylation antibody array mem-
branes, we examined the relative level of phosphorylation
of specific sites for human EGFR receptors. Interestingly,
we noted the phosphorylation of Threonine 686 site of
ErbB2 in all the groups. Studies have suggested that the
dysregulation of cellular protein kinase C [46] and protein
kinase A [47] activity could phosphorylate ErbB2 on Thr-
686 for the activation and proliferation of tumor cells.
However, our findings suggest that ErB2 on Thr-686 may
not be essential for regulation of tumor proliferation, as
tumor control was observed in the PDT + Erbitux treated
group. Phosphorylation of EGFR tyrosine 845, only
noticed in control tumors, is implicated in the stabiliza-
tion of the activation loop, providing a binding surface for
substrate proteins and is capable of regulating receptor
function and tumor progression [48]. c-Src is known to be
involved in the phosphorylation of EGFR at Tyr845 [49].
The major autophosphorylation sites of ErbB2 are
Tyr1248 and Tyr1221/1222 that lead to Ras-Raf-MAP
kinase signal transduction pathway [50]. In control
tumors, ErbB2 was phosphorylated at tyrosine 1221/1222
and is associated with high tumor grade and with shorter
disease-free survival and overall survival [51]. Similarly,
ErbB4 is able to induce phosphorylation of phosphati-
dylinositol 3-kinase regulatory subunit which is a pro-sur-
vival protein that prevents apoptosis [52,53]. Our data
suggests that dephosphorylation of ErbB4 tyrosine 1284 is
critical for tumor regression in the dual treatment group.
EGFR-mediated Ras-Raf-MEK-ERK and PI3K-PTEN-AKT
pathways plays an important role in transmission of sig-
nals from membrane receptors to downstream targets that
regulate apoptosis, cell growth and angiogenesis. Compo-
nents of these pathways include genes such as Ras, B-Raf,
PI3K, PTEN and Akt that can be mutated or aberrantly
expressed in human cancer. Though we did not investi-
gate these genes, it should be noted that they could cause
resistance to anti-EGFR therapy. Numerous studies have
reported Kras mutations as a predictor of resistance to
Erbitux therapy and are associated with poor prognosis in
colorectal cancer [54] and non-small cell lung carcinoma
[55]. In a similar way, Braf mutation is also known to
cause resistance to anti-EGFR therapy in colorectal cancers
[56] and primary lung adenocarcinomas [57]. Mutation
of PTEN tumor suppressor gene in human cancer cells
leads to activated EGFR downstream signaling including
PI3-kinase/AKT and have been linked to resistance to anti-
EGFR targeted therapies [58]. However, in this study we
investigated the role of EGFR target genes cyclin D1 and c-
EGFR expression was assessed in tumor sections using  immunohistochemistry Figure 3
EGFR expression was assessed in tumor sections 
using immunohistochemistry. The brown colored mem-
brane staining indicates EGFR positive immunoreactivity. (A: 
Control, B: PDT, C: Erbitux and D: PDT +Erbitux). Magnifi-
cation: 630×.Molecular Cancer 2009, 8:94 http://www.molecular-cancer.com/content/8/1/94
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myc that are involved in cell proliferation. Our RT-PCR
results showed downregulation of cyclin D1 and c-myc in
the tumors treated with the combination therapy. Ampli-
fication of cyclin D1, a key cell cycle regulatory protein,
appears to be an important event in bladder cancer and is
often associated with cell proliferation and poor progno-
sis in human tumors [59]. In our study, downregulation
of EGFR also resulted in reduction of cyclin D1. This
observation could be due to the administration of Erbitux,
that is known to cause cell cycle arrest in the G(1)/G(0)-
phase, and also increases the expression of cyclin-depend-
ent kinase inhibitors [60]. c-myc, another EGFR target
gene that can obstruct the induction of apoptosis in tumor
cells and lead to uncontrolled cell growth was reduced in
the PDT plus Erbitux treated tumors. Over-expression and
amplification of c-myc can play an important role in met-
astatic progression that indicates poor prognosis in differ-
ent cancers [61]. These results suggest that EGFR target
genes could play a role in tumor inhibition in bladder
cancer by arresting cell cycle growth and inducing apopto-
sis.
Conclusion
In conclusion, combination treatment of PDT and Erbitux
can improve the tumor response of bladder carcinoma
xenografts. In this study, we observed that PDT induced
tumor destruction can be maintained and significantly
enhanced by the administration of Erbitux. As PDT
treated tumors have been shown to adapt to inflamma-
tion and vascular shutdown, and PDT alone may not be
sufficient for effective treatment, there is a need for com-
bination of different modalities to obtain better tumor
response. The challenge is to choose the appropriate anti-
angiogenesis agent in combination with optimal PDT
dosimetry for potential clinical application.
Methods
Photosensitizer
A stock solution of 5 mg/ml hypericin (Molecular Probes,
USA) was prepared by adding 200 μl of dimethyl sulfox-
ide, DMSO (Sigma Aldrich Inc, St Louis Mo, USA) to 1 mg
of hypericin. The stock solution was further diluted in
DMSO and PBS (1:3 v/v) and injected intravenously into
the tail vein based on the weight of the animal at a dosage
of 5 mg/kg.
Dosage of Erbitux (Cetuximab)
Erbitux (Imclone) at a concentration of 2 mg/mL was
administered intraperitonially at a dosage of 10 mg/kg.
Cell culture and xenograft tumor model
MGH bladder cancer cells were cultured as a monolayer in
RPMI-1640 medium supplemented with 10% fetal
bovine serum, 1% non-essential amino acids (Gibco,
USA), 1% sodium pyruvate (Gibco, USA), 100 units/ml
penicillin/streptomycin (Gibco, USA) and incubated at
37°C, 95% humidity and 5% CO2. Before inoculation,
the cell layer was washed with PBS, trypsinized and
counted using a hemocytometer. Male Balb/c nude mice,
6-8 weeks of age, weighing an average of 24-25 g were
obtained from the Animal Resource Centre (ARC), West-
ern Australia. Approximately 3.0 × 106 MGH human blad-
der carcinoma cells suspended in 150 μl of Hanks'
balanced salt solution (Gibco, USA) was injected subcuta-
neously into the lower flanks of the mice. The tumors
were allowed to grow to sizes of 80 to 100 mm3 in volume
before PDT treatment was carried out and the tumors were
measured three times a week.
In vivo treatment protocol
The mice were randomized into 4 groups (10 animals per
group) i.e., (i) Control (mice with untreated tumors), (ii)
PDT only (iii) Erbitux only and (iv) PDT plus Erbitux.
Treatment involved the intravenous injection of hypericin
followed by irradiation with a light source consisting of
filtered halogen light (Zeiss KL1500) fitted with a custom-
Immunofluorescence was performed to confirm the above  results Figure 4
Immunofluorescence was performed to confirm the 
above results. In the confocal images, the green FITC fluo-
rescence staining indicates the expression of EGFR. PDT and 
Erbitux (D) resulted in significant reduction of EGFR expres-
sion of 4-6% (EGFR score 1) compared to monotherapy (B: 
PDT and C: Erbitux) and control groups (A). Maximum 
EGFR tumor cell membrane staining of 21-24% (EGFR score 
3) noticed in the untreated tumors. The monotherapy 
groups of PDT only and Erbitux only, exhibited 15-17% 
(EGFR score 2) and 11-13% (EGFR score 2) staining respec-
tively. Magnification: 400×.Molecular Cancer 2009, 8:94 http://www.molecular-cancer.com/content/8/1/94
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ized 560-640 nm band-pass filter. Light irradiation was
performed 6 h post hypericin administration. A light dos-
age with fluence of 120 J/cm2 and fluence rate of 100 mW/
cm2 was used for PDT treatment. Erbitux was adminis-
tered by intraperitoneal injections (10 mg/kg) at time 0
(immediately after light exposure), 24 h, 48 h and then
every other day up to 90 days post PDT. The mice were
euthanized when either the tumor reached the 2-cm3 eth-
ical limit or at the end of the 90 day monitoring period.
The tumors were harvested and divided into a few sections
for immunohistochemistry, immunofluorescence, pro-
tein and RNA extraction. All procedures were approved by
the Institutional Animal Care and Use Committee
(IACUC), SingHealth, Singapore, and performed in
accordance with international standards.
Immunoblotting
Tissue lysate buffer (T-PER, Pierce, USA) along with pro-
tease inhibitor (Complete Mini, Roche, Germany) was
added to the tumor that was crushed into powder in liq-
uid nitrogen. Tissue and cell debris was removed by cen-
trifugation and the lysate was stored at -80°C until use.
Protein estimation of tumor lysates was performed using
biorad protein assay solution and was quantified using
the GeneQuant pro machine (Biochrom, UK). Following
the addition of sample buffer to the lysates, 50 μg of pro-
tein was resolved onto SDS gel and transferred to nitrocel-
lulose membrane (Pall Corporation, USA) using a TRIS/
glycine/SDS electrode tank buffer, run for 2 h. Membranes
were blocked overnight with 5% low fat milk powder-
TBS-Tween and then washed thoroughly before probing
with the primary antibody 1: 500 (EGFR, Cell Signaling.
USA). After washing with TBS-Tween the membranes were
incubated with HRP-linked secondary antibody (1:1000)
for 1 h. The level of specific protein was visualized by
chemiluminescence (Supersignal, Pierce Techonology,
USA). The membrane was then exposed to X-ray film
(Hyperfilm ECL, Amersham Biosciences, UK) and the sig-
nal was detected using film developer (Kodak M35,
OMAT Processor, USA). The intensities of the signal were
quantified by densitometer (Syngene, USA) and analysed
with GeneTool (Syngene, USA).
Immunohistochemistry
Processing of the samples was done using tissue processor
(Leica TP 1020, Germany). Briefly the tissue samples were
fixed in 10% formalin for 24 h, and then processed in an
ascending series of ethanol and subsequently cleared with
xylene and embedded in paraffin. The paraffin embedded
bladder samples were sectioned at a thickness of 4 μm
using a microtome (Leica RM 2135, Germany). The sec-
tions were mounted on superfrost/plus slides (Fischer Sci-
entific, USA) and air-dried. On the day of staining the
slides were heated in 60°C oven for 1 h and immersed in
zylene for 10 min before rehydration in ethanol series.
Sections were incubated in hydrogen peroxide for 10 min
to block endogenous peroxidase activity. After which, the
sections were incubated with EGFR (BD Biosciences
Pharmingen, USA) primary antibody (1:100) for 1 h. To
confirm the specificity of binding, normal mouse serum
IgG1 (1:500) was used as negative control instead of pri-
mary antibody. Following extensive washing, sections
were incubated for 30 min in the secondary biotinylated
antibody followed by DAB Chromogen (Dako REAL
EnVision Detection System, USA) for 10 min. Sections
were then counter-stained with Harris's hematoxylin and
dehydrated in ascending grades of ethanol before clearing
in xylene and mounting under a cover slip. Images were
captured using image processing software (AxioVision v
4.6.3.0, Carl Zeiss Imaging Solutions, GmbH, Germany).
The images were saved in TIFF format and NIH Image J
v1.62 software was used to analyze and quantify the
expression of EGFR. Briefly, the percentage of positively
stained cells was calculated by obtaining the area of the
immunostained regions divided by the area of the total
image. EGFR scoring was performed based on the preva-
lence of tumor cell membrane staining (EGFR score 1 =
weak intensity and incomplete staining of less than 10%
of tumor cells; score 2 = moderate and complete staining
of between 11 to 20% of tumor cells; score 3 = strong and
complete staining of more than 21 to 30% of tumor cells.)
The tunnel assay was performed on the tumors that were  harvested from the animals at the end of the treatment Figure 5
The tunnel assay was performed on the tumors that 
were harvested from the animals at the end of the 
treatment. Few isolated positive nuclei were noticed in (A) 
untreated tumors, (Apoptotic index (AI) - 6%). Both (B) PDT 
only (AI - 14%) and (C) Erbitux only (AI - 16%) treated 
tumors showed increased apoptosis compared to control. 
High levels of apoptotic nuclei were clearly exhibited by 
tumors treated with the (D) PDT plus Erbitux combination 
therapy (AI - 32%, p < 0.001). Magnification: 630×.Molecular Cancer 2009, 8:94 http://www.molecular-cancer.com/content/8/1/94
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Immunofluorescence
Fresh frozen tissue sections were fixed with 4% parafor-
maldehyde for 2 min. The specimen was blocked for 1 h
with normal goat serum in Triton X-100. After blocking,
sections were incubated overnight with EGFR primary
antibody (Cell Signaling, US) at 4°C. Nonimmune IgG
was used as control. After rinsing in PBS, the specimen
was stained with FITC-conjugated secondary antibody for
2 h at room temperature in dark. Slides were then rinsed
with PBS and stained with DAPI for 30 min. Finally, the
slides were rinsed and mounted with Vectashield® Mount-
ing Medium (Vector Laboratories Inc., USA). Immunoflu-
orescence images were captured using a laser confocal
fluorescence microscope (Meta LSM 510, Carl Zeiss, Ger-
Phosphorylation statuses of EGFR sites were determined using antibody arrays Figure 6
Phosphorylation statuses of EGFR sites were determined using antibody arrays. Increased phosphorylation of 
ErbB2(Thr686), ErbB2(Ser1113) and limited phosphorylation of EGFR(Thy845), ErbB2(Tyr1221/1222), ErbB3(Tyr1289) and 
ErbB4(Tyr1284) sites was seen in the control group. In the monotherapy groups, ErbB2(Thr686), (Ser113) and 
ErbB4(Tyr1284) sites were phosphorylated. Inhibition of most of the EGFR phosphorylation sites was observed in combination 
therapy groups except for ErbB2(Thr686) and (Ser1113). (A: Control, B: PDT, C: Erbitux and D: PDT + Erbitux).Molecular Cancer 2009, 8:94 http://www.molecular-cancer.com/content/8/1/94
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many) and image analysis was performed using the
ImageJ software (1.41o, W. Rasband, National Institute of
Health, USA).
TUNEL assay for DNA fragmentation
Apoptosis was assessed by using the DNA fragmentation
detection kit, TdT- FragEL™ (Oncogene Research Products,
USA). Briefly, 15 μm tissue cryosections were fixed with
4% formaldehyde for 15 min. The slides were then rinsed
in 1× TBS and permeabilised with 20 μg/ml proteinase K
for 10 min at room temperature. A positive control was
generated by adding 1 μg/μl DNase I in 1× TBS/1 mM
MgSO4. Reaction mixture (60 μl) that included 57 μl TdT
Labeling reaction mix and 3 μl TdT enzyme was added to
the sections and left for 1.5 h at 37°C. After rinsing, the
specimens were incubated with HRP conjugate for 30
min. Finally DAB solution was added to the sections to
generate an insoluble colored product at the site of DNA
fragmentation and later counterstained with methyl
green. The TUNEL-stained sections were then examined
under light microscopy to determine the apoptotic indi-
ces. The apoptotic index (AI) was defined as the percent-
age of apoptotic nuclei counted per 1000 neoplastic
nuclei; fields were chosen randomly at 630× magnifica-
tion.
EGFR phosphorylation
A human EGFR phosphorylation antibody array (RayBio-
Tech, USA) was used to simultaneously detect phosphor-
ylation of 17 different sites for Human EGFR in cell
lysates. The cell lysates were prepared from MGH bladder
cancer cells that were treated with PDT, Erbitux alone,
PDT plus Erbitux and control. The components in the kit
included array membranes, biotin-conjugated anti-
cytokines, HRP-conjugated streptavidin and detection
buffer. The manufacturer's protocol was followed to per-
form the experiments. Briefly, the antibody array mem-
branes were treated with blocking buffer, after which the
sample (cell lysate) was added to the membranes and
incubated for 2 h. After extensive washing the membranes
were incubated with cocktail of biotin-conjugated anti-
EGFR was used to detect phosphorylated EGFR on acti-
vated receptors. After incubation with HRP-streptavidin,
the signals were visualized using chemiluminescence. The
membranes were exposed to X-ray film (Hyperfilm ECL,
Amersham Biosciences, UK) and signal was detected using
a film developer (Kodak M35, OMAT Processor, USA).
The intensities of the signal were quantified by densitom-
eter (Syngene, USA). By comparing the intensity of signals
the relative expression levels of the phosphorylated EGFR
sites were determined. Positive control was used to nor-
malize the results from different membranes being com-
pared.
RNA isolation
Total RNA was extracted from tumor tissue using the com-
mercially available Nucleospin RNA II kit (Macherey-
Nagel, Germany). Briefly, the frozen tissue samples were
crushed into powder using liquid nitrogen and lysis
buffer, and β-mercaptoethanol was added to prepare the
lysate. The lysate was then filtered and 70% ethanol was
added to adjust RNA binding to the columns. Later DNA
digestion was performed and pure RNA was eluted. RNA
quality and purity was checked using UV Spectrophotom-
etry and by detecting the ribosomal RNA integrity.
RT-PCR analysis of gene expression
RT-PCR was performed using the Qiagen OneStep RT-PCR
kit. Briefly, a 50 μl final volume containing 10 μl 5× QIA-
GEN OneStep RT-PCR buffer, 2 μl dNTP Mix, 2 μl QIA-
GEN OneStep RT-PCR enzyme mix, 1 μl of RNase
inhibitor, 1.5 μl of forward and reverse primers (at a final
concentration of 0.6 μM) and RNase free water was used
to perform the reaction. Reverse transcription and PCR
was carried out sequentially in the same tube. The result-
ing mixture was heated at 50°C for 30 min, the initial PCR
activation step was performed for 15 min at 95°C, 3-step
cycling of denaturation for 1 min for 94°C, annealing for
1 min at 50-68°C and extension for 1 min at 72°C and 25
cycles was carried out. The final extension was performed
for 10 min at 72°C. Primers were commercially synthe-
sized by Sigma Aldrich. After RT-PCR, 20 μl of individual
RT-PCR product and 2 μl 6× loading buffer (Fermantas,
USA) was electrophoresed in 1.5% agarose gel in TAE
The effect of EGFR inhibition on target genes cyclin-D1 and  c-myc was evaluated at the RNA level Figure 7
The effect of EGFR inhibition on target genes cyclin-
D1 and c-myc was evaluated at the RNA level. Cyclin 
D1 is an important regulator of G1 to S-phase transition and 
overexpression of cyclin D1 has been linked to the develop-
ment and progression of cancer. c-Myc is activated in a vari-
ety of tumor cells and plays an important role in cellular 
proliferation, differentiation, apoptosis and cell cycle pro-
gression. Downregulation of cyclin-D1 and c-myc was 
observed in the tumors treated with PDT and Erbitux (p < 
0.05) when compared with the other groups.Molecular Cancer 2009, 8:94 http://www.molecular-cancer.com/content/8/1/94
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buffer. The gel was viewed and captured as a digital image
by the Gel Documentation System (Bio-Rad Laborato-
ries). Semi-quantitative measurements were derived by
expressing the RT-PCR fragment's band intensity ratio
with gene of interest against actin. The primer sequences
and GenBank accession numbers are as follows: Cyclin
D1 (GenBank No. NM_007631) forward: 5'GGTGC
TTGGGAAGTTGTGTT3' and reverse: 5'CTCCGTCTTTG
TGGTTTGGT3' and c-myc (GenBank No. NM_012333.3)
forward: 5'TTACAAAGCCGCCGACTC3' and reverse
5'CTGCACCAAGGAATAGCTCC3'. β-Actin (GenBank No.
NM_001101.2) forward: 5'TGTCACCAACTGGGACGA
TA3' reverse: 5'TCTCAGCTGTGGTGG TGAAG3'.
Statistical analysis
Tumor volume was calculated by using the formula, vol-
ume = (π/6 × d1 × d2 × d3), where d1, d2 and d3 are
tumor dimensions in 3 orthogonal directions. The effec-
tiveness of the treatment in terms of tumor growth inhibi-
tion was evaluated on day 29 when tumor volumes
reached maximum size in the control group. This was cal-
culated by determining the percentage difference in tumor
growth volumes for the treatment groups compared to
control tumor volume. One-way analysis of variance with
the Bonferroni correction was performed to analyze the
data obtained in this study using Prism 3.0 software
(Graphpad Prism, San Diego, CA). A P value of < 0.05 was
considered to be significant.
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